H.C. Wainwright reiterates Telix stock rating on Regeneron deal By Investing.com

H.C. Wainwright reiterated a Buy rating and $20 price target on Telix Pharmaceuticals after its collaboration agreement with Regeneron, which includes $40 million upfront for four initial programs and up to $2.1 billion in milestone payments plus low double-digit royalties. Telix also reported first-quarter 2026 group revenue of $230 million, up 16% in precision medicine, and FDA acceptance of TLX101-Px with a PDUFA date of September 11, 2026. The stock is up 41% year-to-date to $10.54, though Telix remains unprofitable and analysts do not expect profitability this year.

Analysis

The strategic signal here is less about near-term earnings and more about validation of Telix’s platform by a high-quality partner that can de-risk future capital raises and improve the probability-weighted value of the pipeline. A 50/50 structure implies Regeneron is buying optionality on radiopharma execution without fully owning the operational burden, which is a strong read-through for the sector: clinical-stage imaging/theranostic assets with credible manufacturing and regulatory paths should now command a higher partnership multiple. The upfront cash also matters because it extends runway and reduces the odds of dilutive financing before the next binary inflection.

Second-order, this likely tightens competitive pressure on smaller radiopharma peers that lack either distribution, manufacturing scale, or a marquee collaborator. If the collaboration expands, the real winner is the platform economics around diagnostics plus therapeutics, where commercial leverage is higher than the market typically assigns to single-asset names. The cleaner implication for REGN is that it is signaling willingness to pay for adjacency in an area where its core biologics franchise has less organic exposure; that suggests it may prefer structured partnerships over outright M&A in new modalities.

The market may be underestimating timing risk: the partner announcement is supportive, but monetization is still gated by regulatory execution, reimbursement, and capacity scaling, so the next 6-12 months likely matter more than the headline milestone pool. The main downside is that enthusiasm around optional milestones can overprice a path that is still dependent on safety, label, and manufacturing consistency. If execution slips, the stock can give back quickly because the present value is still concentrated in future optionality, not current profitability.

Key Decisions for Investors

• Long TLX vs short a basket of unpartnered radiopharma peers over the next 3-6 months; the trade captures rerating from external validation while hedging sector beta.
• Add to TLX only on pullbacks toward the post-news support zone, not strength chasing; risk/reward is best if the market gives back 10-15% while partnership sentiment remains intact.
• Use REGN as a low-volatility beneficiary: initiate a modest long only if the market overreacts to partnership spend; downside should be limited given the strategic, not transformational, capital commitment.
• For event-driven upside, buy TLX medium-dated call spreads into the next regulatory/clinical catalyst window; the payoff is asymmetric if the partnership catalyzes multiple expansion before profitability.
• Avoid naked shorting adjacent radiopharma names until there is evidence of capital rotation; partnership enthusiasm can lift the entire sub-sector for several weeks before dispersion appears.